A database of FDA approved therapeutic peptides and proteins
| This page displays user query in tabular form. |
Th1188 details |
| Primary information | |
|---|---|
| ID | 1780 |
| ThPP ID | Th1188 |
| Therapeutic Peptide/Protein Name | Hyaluronidase (Human Recombinant) |
| Sequence | NA view full sequnce in fasta |
| Functional Classification | Ib |
| Molecular Weight | 61000 |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting Point (℃) | NA |
| Half Life | NA |
| Description | A purified preparation of the enzyme recombinant human hyaluronidase. Hyaluronidase (Human Recombinant) is produced by genetically engineered Chinese Hamster Ovary (CHO) cells containing a DNA plasmid encoding for a soluble fragment of human hyaluronidase (PH20). The purified hyaluronidase glycoprotein contains 447 amino acids with an approximate molecular weight of 61,000 Daltons. |
| Indication/Disease | Indicated as an adjuvant to increase the absorption and dispersion of other injected drugs; for hypodermoclysis; and as an adjunct in subcutaneous urography for improving resorption of radiopaque agents. |
| Pharmacodynamics | Hyaluronidase hydrolyzes hyaluronic acid and increase diffusion of injected drugs, thus facilitating their absorption. Hyaluronidase is used for enhancing absorption and distribution of other injected drugs. |
| Mechanism of Action | The family of hyaluronidase enzymes hydrolyzes hyaluronic acid (a glucoseaminoglycan) which is a major constituent of the interstitial barrier. Hyaluronidase (Human Recombinant) is a highly purified recombinant human hyluronidase which lowers the viscosity of the interstitial barrier by breaking down hyaluronic acid and is under investigation as a chemoadjuvant to facilitate local interstitial drug delivery as well as increase bioavilability. |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | NA |
| Volume of Distribution | NA |
| Clearance | NA |
| Categories | NA |
| Patents Number | US7767429 |
| Date of Issue | 23/09/07 |
| Date of Expiry | 23/09/27 |
| Drug Interaction | NA |
| Target | Hyaluronan; Transforming growth factor beta-1 |
| Information of corresponding available drug in the market | |
| Brand Name | NA |
| Company | NA |
| Brand Discription | NA |
| Prescribed for | NA |
| Chemical Name | NA |
| Formulation | NA |
| Physcial Appearance | NA |
| Route of Administration | NA |
| Recommended Dosage | NA |
| Contraindication | NA |
| Side Effects | NA |
| Useful Link | http://www.rxlist.com/rhogam-ultra-filtered-plus-drug/clinical-pharmacology.htm |
| PubMed ID | 16876899, 17683255 |
| 3-D Structure | N.A. |